UNSPSC 51294405: Delfaprazine

This classification denotes an antidepressant agent with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06YTS68E0H, chemically known as 1-(alpha,alpha-phenyl-2,5-xylyl)pi-perazine. but generally known as delfaprazine, which bears US NIH Compound Identifier 205972. European Medicines Agency schedules Delfaprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06953MIG.

UNSPSC 51294405 Delfaprazine is a Commodity code that nominally names a specific pharmaceutical active ingredient, but recent state and local activity under this code reflects broader pharmaceutical procurement spanning naloxone, generic multi-source pharmaceuticals, over-the-counter products, and pharmacy benefit program management. State and local governments are using this code to solicit supply agreements for pharmaceutical products and services that support community health initiatives, emergency response, employee health plans, and institutional healthcare delivery. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work involves product specification, pricing negotiation, wholesaler coordination, compliance certification, and ongoing supply chain management across quarterly or annual delivery cycles.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with authorized wholesaler distribution, proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors must meet FDA requirements, cGMP and Drug Supply Chain Security Act compliance, maintain relationships with specified wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence.